Literature DB >> 17502679

Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins.

Alexander W Tarr1, Ania M Owsianka, Alexandra Szwejk, Jonathan K Ball, Arvind H Patel.   

Abstract

Hepatitis C virus (HCV) infection is a major cause of severe chronic liver disease including cirrhosis and hepatocellular carcinoma. HCV has been classified into six major genotypes that exhibit extensive genetic variability, particularly in the envelope glycoproteins E1 and E2. Knowledge of genotypic and quasispecies variation on viral glycoprotein properties is important in understanding the structure-function relationship of the proteins. Through their perceived role as components of the virion and mediators of virus attachment and entry, HCV glycoproteins are primary targets for the development of antiviral agents. In this chapter, we describe methods optimized to extract E1E2-encoding sequences of all the major genotypes from HCV-infected patient sera, and their amplification, cloning, expression, and biochemical characterization. Furthermore, we describe a method to generate retroviral nucleocapsid pseudotyped with HCV E1E2 of diverse genotypes (HCVpp) whereby infectivity of the retroviral particle is conferred by HCV glycoproteins. Finally, we show how the HCVpp can be used in an infection assay to determine the viral glycoprotein function at the level of the host-pathogen interface and subsequent events leading to virus infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502679     DOI: 10.1007/978-1-59745-393-6_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.

Authors:  Alexander W Tarr; Richard A Urbanowicz; Mohamed R Hamed; Anna Albecka; C Patrick McClure; Richard J P Brown; William L Irving; Jean Dubuisson; Jonathan K Ball
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

2.  Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.

Authors:  Florian Douam; Louis-Marie Bobay; Guillemette Maurin; Judith Fresquet; Noémie Calland; Carine Maisse; Tony Durand; François-Loïc Cosset; Cyrille Féray; Dimitri Lavillette
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

3.  Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.

Authors:  Rachael E Swann; Vanessa M Cowton; Mark W Robinson; Sarah J Cole; Stephen T Barclay; Peter R Mills; Emma C Thomson; John McLauchlan; Arvind H Patel
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 4.  The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.

Authors:  Siobhán B Cashman; Brian D Marsden; Lynn B Dustin
Journal:  Front Immunol       Date:  2014-11-10       Impact factor: 7.561

5.  A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.

Authors:  Richard A Urbanowicz; C Patrick McClure; Richard J P Brown; Theocharis Tsoleridis; Mats A A Persson; Thomas Krey; William L Irving; Jonathan K Ball; Alexander W Tarr
Journal:  J Virol       Date:  2015-12-23       Impact factor: 5.103

6.  Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication.

Authors:  Andrea Magri; Alexander A Ozerov; Vera L Tunitskaya; Vladimir T Valuev-Elliston; Ahmed Wahid; Mario Pirisi; Peter Simmonds; Alexander V Ivanov; Mikhail S Novikov; Arvind H Patel
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

7.  Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.

Authors:  Richard A Urbanowicz; C Patrick McClure; Barnabas King; Christopher P Mason; Jonathan K Ball; Alexander W Tarr
Journal:  J Gen Virol       Date:  2016-07-06       Impact factor: 3.891

8.  Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.

Authors:  Amruta S Naik; Ania Owsianka; Brendan A Palmer; Ciaran J O'Halloran; Nicole Walsh; Orla Crosbie; Elizabeth Kenny-Walsh; Arvind H Patel; Liam J Fanning
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

9.  Understanding the Determinants of BnAb Induction in Acute HCV Infection.

Authors:  Alexander P Underwood; Melanie R Walker; Nicholas A Brasher; Auda A Eltahla; Lisa Maher; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Viruses       Date:  2018-11-21       Impact factor: 5.048

10.  Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.

Authors:  Vasil B Krapchev; Malgorzata Rychłowska; Alicja Chmielewska; Karolina Zimmer; Arvind H Patel; Krystyna Bieńkowska-Szewczyk
Journal:  Virology       Date:  2018-04-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.